Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other research firms have also recently commented on VYGR. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.83.

Voyager Therapeutics Stock Up 4.5 %

NASDAQ:VYGR opened at $7.18 on Friday. The company’s 50 day moving average price is $6.52 and its 200-day moving average price is $7.77. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72. The stock has a market cap of $390.55 million, a price-to-earnings ratio of -143.60 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The firm had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. During the same quarter in the prior year, the company posted ($0.51) earnings per share. As a group, sell-side analysts anticipate that Voyager Therapeutics will post -1.44 earnings per share for the current year.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VYGR. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the period. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. Farallon Capital Management LLC raised its position in shares of Voyager Therapeutics by 77.4% during the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after purchasing an additional 1,000,000 shares during the period. Great Point Partners LLC bought a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at $12,668,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.